What is Advanced Oncotherapy?
Advanced Oncotherapy is at the forefront of developing and providing proton therapy systems, a cutting-edge approach to cancer treatment that leverages advanced technology to deliver superior health outcomes with reduced side effects. The company's proprietary "LIGHT" (Linac Image Guided Hadron Technology) accelerator, developed by its Geneva-based team, represents a significant technological leap. This compact proton accelerator achieves the energy levels of traditional machines but in a unit that is substantially smaller and more cost-effective. This innovation allows for enhanced precision and electronic control in proton beam delivery, surpassing the capabilities of older technologies. Advanced Oncotherapy aims to make this advanced cancer treatment accessible to healthcare providers globally, offering a more effective and less burdensome therapeutic option for patients. The company actively monitors market advancements and seeks strategic partnerships to maintain its position as a leading provider of innovative and affordable particle therapy solutions.
How much funding has Advanced Oncotherapy raised?
Advanced Oncotherapy has raised a total of $23.3M across 5 funding rounds:
Multiple Rounds
$13.3M
Share Placement
$10M
Debt (2017): $3.7M with participation from Blackfinch Investments
Debt (2017): $2.6M led by Blackfinch Investment.
Debt (2017): $1.9M supported by Blackfinch Investment.
Debt (2017): $5.1M, investors not publicly disclosed
Share Placement (2020): $10M backed by SI Capital Ltd
Key Investors in Advanced Oncotherapy
SI Capital Ltd
SI Capital Ltd is an entity that participated in a recent share placement, indicating a strategic interest in the company's growth trajectory and technological advancements.
Blackfinch Investments
Blackfinch Investments is a financial firm that has provided debt financing to Advanced Oncotherapy, supporting its operational and developmental needs through strategic capital allocation.
Blackfinch Investment.
Blackfinch Investment. has been a consistent provider of debt financing, demonstrating confidence in Advanced Oncotherapy's business model and its capacity for future repayment and growth.
What's next for Advanced Oncotherapy?
With the recent major strategic investment and substantial enterprise-level funding, Advanced Oncotherapy is poised for accelerated growth and market penetration. The capital infusion is expected to fuel further development of its LIGHT proton therapy systems, enhance manufacturing capabilities, and expand its global commercial reach. The company's focus on affordability and improved patient outcomes positions it favorably in the competitive oncology market. Future strategic initiatives will likely involve forging new clinical partnerships, securing regulatory approvals in key international markets, and scaling production to meet growing demand. This sustained financial backing provides Advanced Oncotherapy with the resources necessary to solidify its position as a key innovator in the next generation of cancer treatment technologies.
See full Advanced Oncotherapy company page
